Lupin receives USFDA's approval for Hydrocortisone Valerate Cream
16th Aug 2019

Lupin has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (USFDA). Hydrocortisone Valerate Cream USP, 0.2% had an annual sales of approximately $15 million in the US (IQVIA MAT March 2019).

The company’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic version of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries, Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.